4 completed, 1 terminated, 1 unknown. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Critically Ill: new trials by email Literature Review of Critically Ill trials Research Report on Critically Ill
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Goal Nutrition Therapy Guided by Indirect Calorimetry and Nitrogen Balance Among Critically Ill Patients With Acute Kidney Injury (ENGINE Study) indirect calorimetry and nitrogen balance, Indirect calorimetry (Standard care nutrition arm) - Critically Ill, Nutrition Disorders | Phase 1 / Phase 2 | Unknown | Wankawee Jeerangsapasuk | 80 | 2023-03-07 | 2024-02-02 |
| DOSE Trial of Opioid Sparing Effect Fentanyl, Dexmedetomidine - Dexmedetomidine, Mechanical Ventilation Complication | Phase 1 | Terminated | Duke University | 30 | 2019-07-18 | 2021-11-05 |
| Coated Devices to Decrease Infection in the Intensive Care Unit Coated devices, Control - Critically Ill | Phase 1 / Phase 2 | Completed | Hospital do Coracao | 103 | 2019-04-06 | 2020-03-09 |
| Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) Ceftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose - Critically Ill, Pneumonia | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 37 | 2015-02-05 | 2019-08-28 |
| TEAM: A Trial of Early Activity and Mobility in ICU Early mobilisation - Critically Ill | Phase 1 / Phase 2 | Completed | Australian and New Zealand Intensive Care Research Centre | 50 | 2013-08-01 | 2018-08-22 |
| The Use of Methadone in Newborn Infants Methadone - Premature Birth of Newborn, Critically Ill | Phase 1 / Phase 2 | Completed | John van den Anker | 60 | 2010-12-01 | 2018-07-26 |
Critical Illness (6) · Acute Kidney Injury (1) · Nutrition Disorders (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1) · Premature Birth (1) · Sepsis (1)
Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Female Urogenital Diseases and Pregnancy Complications (2) · Infections (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Urogenital Diseases (2) · Cross Infection (1) · Female Urogenital Diseases (1) · Healthcare-Associated Pneumonia (1) · Iatrogenic Disease (1) · Inflammation (1) · Kidney Diseases (1)
Calorimetry, Indirect (1) · Dexmedetomidine (1) · Fentanyl (1) · Inulin (1) · Methadone (1) · Rehabilitation (1) · Tazobactam (1) · ceftolozane (1) · sinistrin (1)
Australian and New Zealand Intensive Care Research Centre (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Duke University (1) · Hospital do Coracao (1) · John van den Anker (1) · Wankawee Jeerangsapasuk (1)
United States (2) · Australia (1) · Brazil (1) · New Zealand (1) · Thailand (1)
Alexandre Biasi, MD/PhD (1) · Carol L Hodgson, PhD (1) · Daniel Benjamin, MD (1) · Wankawee Jeerangsapasuk, Bachelor (1)
PMID 30805946, PMID 32211756, PMID 32526149, PMID 33567333, PMID 36577492
U24TR001608 (1)